Product Name: JAK2-pY570
Product Number: AB-PK668
Size: 25 µg      Price:89.00
      $US
Target Full Name: Janus protein-tyrosine kinase 2

Target Alias: JAK-2; Janus kinase 2; JTK10; Kinase JAK2 ; JAK2_ENST00000381652; JAK2_ENST00000381652; CCDS6457; A8K910; A9QVL8; B4DYV1; Q506Q0; Q52R86; Q8IXP2; ENSG00000096968

Product Type Specific: Protein kinase phosphosite-specific antibody

Antibody Code: PK668

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: Y570

Protein UniProt: O60674

Protein SigNET: O60674

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human JAK2 sequence peptide Cat. No.: PE-04ADB95

Antibody Immunogen Sequence: VGD(pY)GQL(bA)C

Antibody Immunogen Description: Corresponds to amino acid residues V567 to L573; In the protein kinase catalytic domain.

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Potency: Strong immunoreactivity of a target-sized protein by Western blotting in HepG2 and HeLa cells. Very strong immunoreactivity with immunogen peptide on dot blots. Strong immunoreactivity with recombinant human JAK2 on protein dot blots.

Antibody Species Reactivity: Human

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 125-135 kDa.

Antibody Specificity: High-very high

Antibody Cross Reactivity: Strong immunoreactivity on protein dot blots with with recombinant human JAK3, medium immunoreactivity with TYK2 and weak immunoreactivity with JAK1. No significant cross-reactive proteins detected in HepG2 and HeLa cells.

Related Product 1: JAK2-pY570 blocking peptide

Related Product 2: JAK2-2 pan-specific antibody (Cat. No.: AB-NK085-2)

Related Product 3: JAK2-3 pan-specific antibody (Cat. No.: AB-NK085-3)

Related Product 4: JAK2 pan-specific antibody (Cat. No.: AB-NK085-3P)

Related Product 5: JAK2-4 pan-specific antibody (Cat. No.: AB-NK085-4)

Related Product 6: JAK2-pY1007+pY1008 phosphosite-specific antibody (Cat. No.: AB-PK667)

Related Product 7: JAK2Selectide - JAK2 protein kinase substrate peptide

Related Product 8: IRS1 (891-902) KinSub - Insulin receptor substrate 1 (K891-G902) mouse, peptide; IGF1Rtide protein kinase substrate peptide

Related Product 9: IRS1 (891-902) KinSub - Insulin receptor substrate 1 (K891-G902) mouse, peptide; IGF1R protein kinase substrate peptide

Scientific Background: JAK2 is a protein-tyrosine kinase of the TK group and JAKA family. It is a non-receptor kinase involved in the regulation of various cellular processes, including cell cycle progression, development, differentiation, and histone modifications. Additionally, JAK2 plays a critical role in the signalling events of both innate and adaptive immunity as well as erythropoiesis. JAK2 can pair with type I receptors to mediate signalling for GHR (growth hormone), PRLR (prolactin), (LEPR) leptin, EPOR (erythropoietin), and THPO (thrombopoietin). JAK2 can also pair with type II receptors to mediate the effects of IFN-alpha, IFN-beta, IFN-gamma, and various interleukins. It is activated by phosphorylation at Y613, and Y972, and Y1008. JAK2 signalling has been implicated in in a wide range of human hematologic malignancies, and this is typically accompanied by the over-activation of the STAT5 transcription factor, which is a substrate. Polycythemia vera, thrombocythemia, and myelofibrosis are classified as clonal myeloproliferative diseases that arise from a multipotent progenitor cell type. These often rare diseases are characterized by excess production of abnormal cells, displacing healthy cells. JAK2 is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. A high percentage of patients with these myeloproliferative diseases have a dominant gain-of-function substitution mutation, V617F, in the JAK2 gene sequence. For example, the V617F mutation was observed in 40 of 45 polycythemia vera patients. The mutation was observed to cause constitutive tyrosine phosphotransferase activity that promoted erythrocytosis in a mouse model.
Figure 1. Epitope mapping of JAK2-pY570 antibody with similar phosphopeptides on dot blots.


Figure 2. Identification of phosphosites related to JAK2-pY570.